Avantect® Pancreatic Cancer Test
Early detection of pancreatic cancer
Approved/CommercialNYSDOH approved; CMS reimbursement; Enhanced version launched Feb 2026.
Key Facts
Indication
Early detection of pancreatic cancer
Phase
Approved/Commercial
Status
NYSDOH approved; CMS reimbursement; Enhanced version launched Feb 2026.
Company
About ClearNote Health
ClearNote Health is a commercial-stage diagnostics company leveraging its unique epigenomics platform to detect high-mortality cancers early via a simple blood draw. The company's core technology measures 5-hydroxymethylcytosine (5hmC) modifications in cell-free DNA, providing a sensitive and specific signal of developing cancer. Key achievements include NYSDOH approval and CMS reimbursement for its Avantect tests, selection for the NCI's Vanguard study, and a strategic focus on pancreatic and ovarian cancers. The company is expanding its leadership and commercial footprint to drive clinical adoption.
View full company profile